NP-160 / Algernon Pharma - LARVOL DELTA

Draft genome analysis of antimicrobial Streptomyces isolated from Himalayan lichen. (PubMed, J Microbiol Biotechnol) - "Although NP160 had 100% similarity with the alkylresorcinol biosynthetic gene cluster, our results showed low similarity with existing members of this biosynthetic gene cluster, and most have not yet been revealed. In conclusion, we expect that lichen-associated bacteria from the Himalayas can produce new secondary metabolites, and we found several secondary metabolite-related biosynthetic gene clusters to support this hypothesis."

Journal

Newly added product (GlobeNewswire) - Preclinical, Non-alcoholic Steatohepatitis

Pipeline update

Nash Pharmaceuticals announces 84% reduction of fibrosis by additional lead compound in second pre-clinical study for non-alcoholic fatty liver disease (GlobeNewswire) - "Nash Pharmaceuticals Inc....announce that its lead compound for non-alcoholic steatohepatitis ('NASH') NP-160 showed repeated positive results in a recently completed study investigating its therapeutic effects in the widely used STAM™ mouse model from SMC Laboratories....Data from this study demonstrated statistically significant improvements...Cenicriviroc (40 mg/kg, QID) both a positive control and comparator arm in the study showed a 1.5 point drop in the NAFLD/NAS score vs controls; NP-160 (40 mg/kg, QID) showed a 1.25 point drop in the NAFLD/NAS score vs controls (p<0.05)..."

Preclinical